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Fosphenytoin sodium (PubChem CID: 56338)There is an increasing interest in the intranasal delivery of central nervous system-active drugs due to the exis-
tence of a direct nose-to-brain connection. However, poor solubility limits the amount of drug that can be admin-
isteredwithin an aqueous solution. In the presentwork, the objectiveswere to develop an ex vivo bioconversion/
permeability evaluation method and to study the ex vivo bioconversion of the hydrophilic phosphate ester
prodrug fosphenytoin (FOS) to the active drug phenytoin (PHT) and their comparative nasal permeation.
Bioconversion/permeability studies were performed in excised porcine nasal mucosa mounted in Ussing cham-
bers. The physical integrity of the tissues was evaluated by measurement of the transepithelial electrical resis-
tance (TEER). The simultaneous quantitative assay of FOS, PHT and its major metabolite, 5-(4-hydroxyphenyl)-
5-phenylhydantoin (HPPH) was developed and validated according to international guidelines using a liquid
chromatography analytical method. The FOS bioconversion rate and PHT and FOS apparent permeability coeffi-
cients (Papp) were determined at different time points. FOS bioconversion was also qualitatively investigated in
human nasal mucus.
The developed liquid chromatography method combines a fast and inexpensive sample preparation with inacti-
vation of the enzymatic metabolism of the prodrug during sample manipulation and storage. It was linear, pre-
cise, accurate, and presented a high analyte recovery. FOS was converted ex vivo to PHT but the metabolite
HPPHwas not detected. The bioconversion rate increasedwith FOS concentration andwith time, which suggests
a diffusion-limited process. FOSwas also converted to its active drug by human nasal mucus. A novel mathemat-
ical data analysis method was developed to reduce the bias introduced by variable mucosal TEER in the perme-
ability results. At comparable FOS and PHT concentrations the ln(Papp
PHT) of both compounds showed little
difference, which indicates that the use of a hydrophilic and charged prodrug did not hinder overall drug perme-
ation. At the highest tested FOS concentration it was possible to quantify FOS in the receiver chambers, meaning
that at a sufficiently high concentration the FOS permeation rate overcame its bioconversion rate. The ln(PappPHT)
tended to similar equilibrium values as the assay progressed, but with higher FOS concentrations that equilibri-
um was attained faster. Acidic pH reduced the permeability of both PHT and FOS.
The developed bioconversion/permeability evaluation method will constitute an important tool to select the
most promising formulations before proceeding to in vivo studies. Importantly, it allowed the demonstration of
phosphatase activity and FOS bioconversion in nasal mucosa, as well as the prodrug's nasal permeation potential.
Furthermore, this study demonstrates the possibility of formulating phosphate prodrugs of poorly soluble central
nervous system-active drugs as a strategy to increase the solubilized drug doses administered through the nasal
route.
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s).1. Introduction
Central nervous system (CNS) diseases affect over 1.5 billion people
worldwide andwill become themain health problem of the 21st centu-
ry, which entails a large burden to healthcare systems worldwide
(Palmer, 2010). This grim reality highlights the need to devote increas-
ing research time and means to the development of new and improved
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eases is difficult because the blood-brain barrier limits the passage of
most drugs. Furthermore, even those that are able to cross it frequently
present limitations such as poor bioavailability, first-pass metabolism
and peripheral side effects when administered orally (Serralheiro
et al., 2013b).
In order to circumvent someof the drawbacks of the oral administra-
tion of CNS-active drugs, intranasal delivery has been gaining promi-
nence as an alternative route because, besides allowing the passage of
drugs to the systemic circulation, it has the ability to bypass the
blood-brain barrier and directly target drugs to the CNS,mainly through
olfactory and trigeminal nerve pathways, in a non-invasive manner
(Mittal et al., 2014). Plus, intranasal delivery provides a fast onset of
therapeutic action, which is of utmost importance in emergency situa-
tions such as status epilepticus (Serralheiro et al., 2013b). Just consider-
ing the application of the intranasal route of administration to the brain
delivery of antiepileptic drugs, there are promising results from in vivo
studies of carbamazepine (Barakat et al., 2006; Samia et al., 2012;
Serralheiro et al., 2014), lamotrigine (Serralheiro et al., 2015), valproic
acid (Eskandari et al., 2011), clobazam (Florence et al., 2011), clonaze-
pam (Vyas et al., 2006), among others. Despite all its advantages, intra-
nasal delivery also presents some hindrances such as the small volumes
that can be administered through this route (25–200 μL), which is prob-
lematic for poorly soluble drugs, that encompass many existent drugs
and around 40% of the molecules under development (Alelyunas et al.,
2010; Bahadur and Pathak, 2012). For such drugs, unless they are ex-
tremely potent, the most common approach of formulating simple
aqueous solutions (Jogani et al., 2008) is clearly not adequate, and alter-
native formulation strategies are required.
Since the nasal epithelium is a highly permeable membrane
(Bahadur and Pathak, 2012) and there is extensive work on permeation
enhancing excipients for nasal drugs (Illum, 2012), we hypothesized
that the use of soluble prodrugs (Stella and Nti-Addae, 2007) would
be a valuable strategy for the design of nasalmedicines of poorly soluble
CNS-active drugs such as phenytoin (PHT). This is an anticonvulsant
with limited aqueous solubility (20–25 μg/mL) (Stella, 1996) pertaining
to the class II of the biopharmaceutics classification system (Heimbach
et al., 2003) that presents some drawbacks: an erratic absorption
when administered through the oral route (Atef and Belmonte, 2008)
and is predominantly metabolized by cytochrome P450 (CYP) 2C9/10
to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) (Chollet, 2002), a
metabolite that has been associated with one of the most common
side effects of this drug, gingival hyperplasia (Ieiri et al., 1995; Kamali
et al., 1999). PHT has a commercially available hydrophilic phosphate
ester prodrug, fosphenytoin (FOS), that is rapidly converted to its parent
active drug by alkaline phosphatases (Stella, 1996) and was selected as
the model molecule to test our hypothesis.
The primary objective of this work was to develop a fast, inexpen-
sive, and accurate ex vivo FOS and PHTnasal bioconversion/permeability
evaluation method, using porcine nasal mucosa. This included the de-
velopment, optimization, and validation of a liquid chromatography
(LC) analytical method for the simultaneous determination of theFig. 1. Chemical structures of fosphenytoin (FOS), phenytoin (PHT), 5-(4-hydroxyphenyl)-5-ph
standard (IS).concentrations of FOS, PHT and HPPH (Fig. 1) in the media of both
donor and receiver compartments of Ussing chambers, which is de-
scribed herein for the first time. The second aim of the present work
was to evaluate whether there is bioconversion of FOS to PHT by the
mucosa, and to study their comparative nasal permeation in simple
buffered solutions.
2. Material and Methods
2.1. Chemicals
Sodium di-hydrogen phosphate anhydrous and theAmerican Chem-
ical Society (ACS) reagent grade chemicals potassium chloride, calcium
chloride dehydrate, sodium hydrogen carbonate and perchloric acid
70% were from Panreac Química S.A.U. (Castellar del Vallès, Barcelona,
Spain). di-Sodium hydrogen phosphate anhydrous (ACS reagent
grade) was from Panreac AppliChem (Darmstadt, Germany). Sodium
chloride (Analytical reagent grade), D-glucose anhydrous (Analytical re-
agent grade),methanol (HPLC grade) and triethylamine (Laboratory re-
agent grade) were from Fischer Scientific UK (Loughborough,
Leicestershire, United Kingdom). Magnesium chloride hexahydrate,
5,5-diphenylhydantoin sodium salt (commonly known as phenytoin
sodium) (N99%), 10,11-dihydrocarbamazepine (N99%) and 5-(4-
hydroxyphenyl)-5-phenylhydantoin (98%) were purchased from
Sigma-Aldrich, Inc. (St. Louis, Missouri, United States of America).
Fosphenytoin sodium USP (99.88%) was kindly supplied by JPN Pharma
(Tarapur, Maharashtra, India). Ultrapure water was used throughout
the work (Milli-Q water system, Merck Millipore, Billerica, Massachu-
setts, United States of America).
2.2. Tissue Preparation and Ussing Chamber Set Up
Nasal mucosa was excised from freshly slaughtered pigs in the
nearest slaughterhouse (Oviger, Alcains, Castelo Branco, Portugal). The
nasal tissue was obtained by cutting the pig heads in two halves by
the septum, followed by its removal and unrolling of the nasal concha
in order to access the upper lateral region of the cavity mucosa. A rect-
angular piece of mucosa was cut with a scalpel, transferred with twee-
zers to a falcon tube and put on ice for immediate transport to the
laboratory. Immediately before mounting, the mucosas were immersed
and gently washed in ice-cold oxygenated Krebs-Ringer Bicarbonate
(KRB) buffer adjusted to pH 7.4 (1.5 mM NaH2PO4, 0.83 mM Na2HPO4,
1.67 mMMgCl2, 1.20 mM CaCl2, 4.56 mM KCl, 15 mM NaHCO3, 10 mM
D-glucose and 119.78 mM NaCl, saturated with oxygen by gassing it
with a mixture of 95%/5% O2/CO2 (Osth et al., 2002a)). Square pieces
of nasal mucosa were cut and mounted on NaviCyte vertical 9 mm cir-
cular Ussing chambers with an exposed tissue surface area of 0.64 cm2
(Warner Instruments, Holliston, Massachusetts, United States of
America). A heater block (Warner Instruments) connected to an exter-
nal circulating water bath set to 37 °C was used, leading to an actual
equilibrium temperature of about 33 °C in the Ussing chambers.enylhydantoin (HPPH), and 10,11-dihydrocarbamazepine, which was used as the internal
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and receiver, bathing the mucosal and submucosal sides, respectively).
The media circulation and stirring was assured through a gas-lift pro-
cess using the incorporated gasmanifold of the heater blockwith amix-
ture of 95%/5% O2/CO2 (1–2 bubbles/s).2.3. Tissue Integrity
The physical integrity of the nasal mucosa was assessed by measur-
ing the transepithelial electrical resistance (TEER) using an EVOM2, Ep-
ithelial Voltohmmeter and its STX2 “chopstick” electrodes containing a
silver/silver-chloride pellet and a silver electrode from World Precision
Instruments (Sarasota, Florida, United States of America). In order to
compensate for the electrical resistance of the Ussing chambers and
buffer media, a control chamber was left without nasal mucosa, taking
care to prevent leaking. The TEER (Ω·cm2) of eachmucosawas thus cal-
culated by subtracting the electrical resistance of the control chamber
from the electrical resistance of the Ussing chambers containing nasal
mucosa and multiplying the result by the exposed tissue area
(0.64 cm2). TEER measurements were performed right after adding
KRB to the Ussing chambers, after 30 min of preincubation to allow
the buffer and mucosas to reach the desired temperature and a state
of electrophysiological equilibrium and at the end of the permeability
studies. The inclusion criterion for the mucosas was that the TEER was
between 15 and 45 Ω·cm2 after the preincubation time. If any mucosa
did not fulfill this criterion, it was replaced by a different one and the
preincubation period was reset.2.4. Bioconversion and Permeability Studies
The drug or prodrug donor solutions for the bioconversion and per-
meability studies were prepared in oxygenated KRB, pH 7.4, or oxygen-
ated phosphate buffer adjusted to pH 4.5 (25 mM NaH2PO4, 1.67 mM
MgCl2, 1.2 mM CaCl2, 4.56 mM KCl, 10 mM D-glucose and 119.78 mM
NaCl in ultrapurewater, saturatedwith oxygen by gassing it with amix-
ture of 95%/5% O2/CO2).
After the preincubation and TEER measurements described in
Section 2.3, the buffer was replaced in the receiver chambers by
3.5 mL of fresh prewarmed KRB and by 3.5 mL of prewarmed drug or
prodrug donor solution in the donor chambers.
In the experiments with PHT, 25 μL samples were collected from the
donor chambers at the beginning of the incubation (initial drug concen-
tration) to microtubes containing a mixture of 20 μL of perchloric acid
(PCA) 10% and 75 μL of blank matrix (KRB that was incubated with
nasal porcine nasal mucosa for an equivalent time of the complete
assay without any drug). One hundred μL samples were collected from
the receiver chambers at 30min intervals, up to 120min, to microtubes
containing 20 μL of PCA 10%. In the experiments where FOSwas used, in
order to determine the initial concentration of FOS, 10 or 25 μL samples
(according to the prodrug concentration and consequent necessary di-
lution) were collected from the donor chambers at the beginning of
the incubation period tomicrotubes containing 90 or 75 μL of blankma-
trix, respectively, and 20 μL of PCA 10%. After that, different sample vol-
umes (according to the necessary dilution) for the donor chambers and
100 μL samples for the receiver chambers were collected and trans-
ferred to microtubes containing 20 μL of PCA 10% at 30 min intervals,
up to 120 min. This procedure was used to quantify FOS and PHT con-
centrations in the receiver and donor chambers, and thus determine
the total amount of PHT that was being formed during the assay and es-
timate the bioconversion rate of this process. Samples were thoroughly
mixed with the blankmatrix and/or PCA 10% by using a vortex mixer at
each collection time and stored at−20 °C at the end of the study, until
further sample preparation (as described in Section 2.6.3) and LC anal-
ysis, within the validated stability timeframe.2.5. Qualitative Evaluation of FOS Bioconversion by Human Nasal Mucus
Nasalmucuswas self-collected by three human volunteers by gently
scrubbing a sterile plastic loop on the interior wall of the nasal cavity.
Each mucus sample was mixed with 0.4 mL of a FOS solution
(29 μg/mL in KRB, pH 7.4) by immersion of the loop in the solution,
and incubated at 37 °C. At each time point (1, 2.5 and 4 h), a sample
was collected for quantification of FOS and PHT as described in
Section 2.4. Thiswas a simple, safe and non-invasive procedure to inves-
tigate the occurrence of FOS bioconversion in human nasal mucus.
2.6. Analytical Method
2.6.1. Stock Solutions, Calibration Standards and Quality Control Samples
Stock solutions (5 mg/mL) of PHT, FOS, HPPH and IS were individu-
ally prepared in methanol and stored at−80 °C. From these stock solu-
tions, individual intermediate solutions for all analytes (100 μg/mL)
were prepared by dilution with methanol to facilitate the preparation
of the lowest concentrated spiking solutions. A working solution of IS
(100 μg/mL), for a final concentration of 14.3 μg/mL, was prepared in a
mixture of water-methanol (50:50, v/v) and stored at 4 °C. Eleven com-
bined (PHT, FOS and HPPH) spiking solutions with final concentrations
of 0.2, 0.4, 1, 3, 10 and 30 μg/mL for the calibration standards and 0.2,
0.6, 15, 27 and 150 μg/mL (15 μg/mL after a tenfold dilution) for the
quality control (QC) samples were also prepared in a mixture of
water-methanol (50:50, v/v) and stored at 4 °C. Six calibration stan-
dards in the concentration range of 0.2–30 μg/mL were prepared daily
by spiking 80 μL aliquots of blank matrix (obtained as explained in
Section 2.4), containing 20 μL of PCA 10%, with 20 μL of the appropriate
combined spiking solutions and 20 μL of IS working solution. QC sam-
ples at four concentration levels covering the calibration curve range,
more specifically, the lower limit of quantification (LLOQ; QCLLOQ), low
(QC1), medium (QC2) and high (QC3) concentrations were indepen-
dently prepared daily in the same manner as the calibration standards
to monitor the performance of the analytical method. Additional QC
samples only containing FOS at the high concentration level (QC3FOS)
were similarly prepared just for the stability studies. In order to evaluate
the dilution integrity (tenfold dilution), another QC sample (QCDil) was
prepared daily by spiking 80 μL of blankmatrixwith 20 μL of the highest
concentrated combined spiking solution, followed by the transfer of
10 μL of the obtained mixture to a microtube containing 20 μL of PCA
10% and 90 μL of blank matrix and then spiked with 20 μL of IS working
solution.
2.6.2. Equipment and Chromatographic Conditions
The chromatographic analysis was performed in anultrahigh perfor-
mance liquid chromatography (UHPLC) system (1290 Infinity Binary LC
System) coupled to a diode array detector (1260 Infinity DAD; G4212B),
both from Agilent Technologies (Santa Clara, California, United States of
America). All components were controlled using the ChemStation soft-
ware, also from Agilent Technologies. The chromatographic separation
of FOS, PHT, HPPH, and IS was achieved in 15 min at 30 °C on a
reversed-phase LiChroCART® Purospher® STAR column (C18,
55 mm × 4 mm; 3 μm particle size) from Merck KGaA (Darmstadt,
Germany). The aqueous component of themobile phasewas composed
of 10 mM NaH2PO4 and 0.25% triethylamine (v/v) in ultrapure water,
with the pH adjusted to 3.0, and the organic component was methanol.
The final ratio of aqueous-organic components (64:36, v/v) was
achievedwith the JetWeaver V35Mixer of the UHPLC system. This mo-
bile phase was pumped isocratically at a flow rate of 1.0mL/min, the in-
jection volume was 20 μL and the detection was carried out at a
wavelength of 215 nm for both the analytes and IS.
2.6.3. Sample Preparation
Frozen samples from the bioconversion and permeability studies,
containing 20 μL of PCA 10%, were allowed to reach room temperature
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were centrifuged for 5 min at 13,000 RPM (16,060 RCF) at room tem-
perature in a MIKRO 20 centrifuge from Hettich (Tuttlingen,
Germany) and 100 μL of supernatants were transferred to the sample
glass vials of the chromatographic system for injection.
2.6.4. Analytical Method Validation
The method was validated according to the international guidelines
for bioanalytical method validation of the Food and Drug Administra-
tion (FDA) and European Medicines Agency (EMA) and considering
their acceptance criteria for selectivity, linearity, LLOQ, precision, accu-
racy, dilution integrity, recovery and stability (European Medicines
Agency, 2011; U.S. Food and Drug Administration, 2001).
The selectivity of the method was evaluated by analyzing six inde-
pendent samples of blank matrix (obtained as described in
Section 2.4) to ensure that there was no significant interference from
endogenous compounds,metabolites or degradation products at the re-
tention times of FOS, PHT, HPPH, and IS.
In order to study the linearity, calibration curves were prepared
using the calibration standards described in Section 2.6.1 and assayed
on five different days. The homoscedasticity of the calibration curves
was evaluated and the data were subjected to a weighted least squares
linear regression using 1/y2 as the weighting factor, according to a pro-
cedure developed by Almeida et al. (Almeida et al., 2002). Calibration
curves were only accepted if the back-calculated concentrations of the
calibration standards deviated no more than ±15% from the nominal
concentration value (±20% for the LLOQ).
The LLOQwas defined by analyzing five replicates and verifying that
the analyte response was at least five times higher than the blank
response.
The inter-day precision and accuracy of the method was studied by
analyzing QC samples on five different days, while the intra-day preci-
sion and accuracy of the assay was determined by analyzing five repli-
cates of the QC samples in a single day. The acceptance criteria were
as follows: precision (expressed as percentage of the coefficient of var-
iation, CV) must be lower than or equal to 15% (20% for the LLOQ) and
accuracy (expressed as bias) must be within ±15% (±20% for the
LLOQ).
In order to determine the dilution integrity, QCDil samples were an-
alyzed on five different days and on the same day using the 15% criteria
for inter and intra-day precision and accuracy, respectively.
To assess the recovery of the analytical method, the absolute recov-
ery of the analytes and IS was determined in QC1, QC2 and QC3.
The stability studiesweremade usingQC1 andQC3, aswell as QC3FOS,
containing only FOS to better investigate its stability due to the possible
conversion of FOS to PHT during sample manipulation and storage. Sta-
bility in the different tested conditionswas acceptedwhen the stability/
reference samples ratio stayed within 85–115%. In order to simulate
sample handling and storage before analysis, the short-term and long-
term stability of unprocessed samples was evaluated at room tempera-
ture for 4 h and−20 °C for 28 days. Furthermore, the post-preparative
stability of processed samples was also determined at room tempera-
ture for 24 h in order to simulate the maximum time that samples
might have to stay in the UHPLC autosampler before being analyzed.
2.7. Data Analysis and Papp Weighting
The experiments were repeated at least in five different mucosa
pieces (n = 5–10) and data were expressed as mean ± standard error
of the mean (SEM). Both linear regression analysis and analysis of vari-
ance (one-way or two-way ANOVA, followed by a Sidak or Tukey post-
hoc test) were performed using the trial version of GraphPad Prism® 6
for Mac from GraphPad Software, Inc. (La Jolla, California, United States
of America). The bioconversion surface plot was constructedwith JMP®
Pro 11 for Mac from SAS Institute Inc. (Cary, North Carolina, United
States of America), kindly provided by SAS Institute, Software, Lda.(Lisbon, Portugal). A p-value of 0.05 was considered as theminimal sig-
nificance level for the statistical tests.
The FOS to PHT bioconversion rate (μM/min/cm2) was calculated
using the following equation:
Bioconversion rate ¼ PHT½ T= t  Að Þ; ð1Þ
where [PHT]T (μM) is the combination of the molar concentration of
PHT in both the donor and receiver chambers at the different sampling
times, t (min) is the incubation time and A (cm2) is the exposed area of
the porcine nasal mucosa.
The permeability of both PHT and FOS through the nasalmucosawas
estimated by calculating the apparent permeability coefficient (Papp)
(10−6 cm/s) according to the following general equation:
Papp ¼ 106  Q= C0  t  Að Þ; ð2Þ
where Q (nmol) is the totalmolar amount of PHT or FOS that permeated
to the receiver chambers during the incubation time, C0 (μM) is the ini-
tial PHT or FOS molar concentration in the donor chambers, t (s) is the
incubation time and A (cm2) is the exposed tissue area.
Eq. (2) can also bewritten discriminatingwhich drugwas quantified
as follows:
PPHTapp ¼ 106  QPHT= C0  t  Að Þ; ð3Þ
and/or
PFOSapp ¼ 106  QFOS= C0  t  Að Þ; ð4Þ
where QPHT andQFOS (nmol) are, respectively, the totalmolar amount of
PHT and FOS that permeated to the receiver chambers during the incu-
bation time. When a FOS solution was used in the donor chambers, its
permeability was expressed as PappPHT or, when QFOS was above the
lower limit of quantification of the analytical method, both PappPHT and
PappFOS.
Considering the high inter- and intra-assay variability of the TEER
values, which we were unable to control, and their influence in PappPHT
and PappFOS, we developed a weighting system to eliminate, as much as
possible, the interference of TEER on permeability, by calculating what
the permeability would have been if TEER had a constant value. After
converting the experimental Papp values to their natural logarithm
[ln(Papp)exp] to obtain a normal distribution (which has already been
done in similar works (Osth et al., 2002a)), the linear function equation
between ln(Papp) and TEER was derived by linear regression. In the re-
gression equation of the type y = mx + b, y is the predicted ln(Papp)
[ln(Papp)pre] and x is the average TEER (μTEER) from the measurements
taken in each experiment at the end of the preincubation time and at
the end of the permeability assay. Therefore we have:
ln Papp
 
pre ¼ m  μTEER þ b: ð5Þ
The linear regression acceptance criteriawere a F-test p-value b 0.05,
a coefficient of determination (r2) N 0.5, compliance with the assump-
tion of normality of the residuals (p-value N 0.05) by the D'Agostino-
Pearson omnibus K2 test and meeting of homoscedasticity (visual veri-
fication that the residuals were randomly distributed around the x-
axis of a Residual vs μTEER plot).
The residuals (ε) were calculated as follows:





so, by combining Eqs. (5) and (6) we get:
ε ¼ ln Papp
 
exp− m  μTEER þ bð Þ: ð7Þ
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sidering a constant reference value of TEER, chosen to be the average
from all permeability studies (25.4 Ω·cm2). The individual weighted
ln(Papp) [ln(Papp)w] values were finally calculated by adding the
residuals resulting from the linear regression to the predicted
ln(Papp) [ln(Papp)pre]. The equation is:
ln Papp
 
w ¼ m  25:4þ bð Þ þ ln Papp
 
exp− m  μTEER þ bð Þ; ð8Þ
Eq. (8) can be further simplified to:
ln Papp
 
w ¼ ln Papp
 
exp þm  25:4−μTEERð Þ: ð9Þ
3. Results and Discussion
3.1. Development and Optimization of the Experimental Conditions for the
Ex Vivo Bioconversion and Permeability Studies
Porcine nasal mucosa mounted in vertical Ussing chambers was se-
lected as the basis for the bioconversion and permeability evaluation, as
it was considered an effective and economic method both for the pres-
ent work and for screening purposes during the initial stages of future
formulation development. This ex vivo approach, which is based on
the use of excised tissues, allows greater resemblance to in vivo condi-
tions than regular cell culture methods (Merkle et al., 1998; Osth
et al., 2002a). Concerning the intranasal route of administration, having
in account the obvious difficulties in obtaininghuman tissues fromnasal
biopsies, the selected model follows the tendency of most published
studies, which are performed in animal nasal mucosa mounted in
Franz diffusion cells or Ussing chambers in combination with electro-
physiological measurements to assess tissue integrity (Merkle et al.,
1998). Even though themajority of researchers used to resort to tissues
from rabbits, cows and sheep (Merkle et al., 1998; Schmidt et al., 2000),
recently, porcine nasal mucosa has been used in a large array of studies,
both with small molecule drugs and proteins in simple solutions or
more complex formulations (Carvalho et al., 2013; Osth et al., 2002b;
Samson et al., 2012; Sintov et al., 2010; Wadell et al., 2003). In addition
to the similarities to humans regarding general morphology, cell types
and electrophysiological parameters (Wadell et al., 1999), this model
is also advantageous from an ethical point of view, because only animals
already intended for slaughter are used, and it offers a considerable tis-
sue area. Furthermore, the viability (cell metabolic activity) of porcine
nasal mucosa in ex vivo studies has already been validated (Wadell
et al., 1999). We also qualitatively confirmed the viability of the muco-
sas using resazurin,whichwas reduced to resorufin, indicating the pres-
ence of metabolic active cells (data not shown).
Nasal cavity mucosa was used since septum mucosa has pervasive
connective tissue that greatly influences drug permeability (Wadell
et al., 1999).We also found that even though septummucosawas easier
to excise, it was less homogeneous than nasal cavity mucosa in thick-
ness and appearance, showing a large variability between different an-
imals, which is further reinforced by results that showed a greater
coefficient of variation in the determination of electrophysiological pa-
rameters (Wadell et al., 1999).
The usage of biological membranes requires special care in their
handling and strict control over the buffer media, pH, temperature
and oxygenation because it is crucial to assure the physical integrity
and viability of the tissues (Maitani et al., 1997; Wadell et al., 1999)
and, therefore, the reliability of the results.
The integrity of the tissues, more specifically of its tight junctions,
was assessed by measuring the TEER (Osth et al., 2002a) because it is
easy to determine and it has already been used as the single electro-
physiological parameter for that purpose in other permeability studies
with Ussing chambers (Fortuna et al., 2012).We also tested two procedures for the transport of the mucosas to
the laboratory after excision: in gassed KRB (wet) and on dry tubes
(dry) placed on ice. This was done by periodically comparing the TEER
of mucosas transported in both conditions during 180 min (60 min of
preincubation and 120 min of incubation). No substantial differences
were found between tissues transported by wet or dry methods
(Fig. S1 of the Supplementary material) and as a result, the dry method
was chosen to simplify the procedures.
Having in account that the usual preincubation times to reach a state
of electrophysiological equilibrium vary between 20 and 120 min
(Merkle et al., 1998), we measured the TEER at 0, 30 and 60 min of
preincubation to evaluate how it changed during this period. Thirty
min was selected as the final preincubation time because, even though
the TEER suffered a sharp decline during the first 30 min, it remained
fairly stable after that (Fig. S2 of the Supplementarymaterial), which in-
dicates that this time is sufficient to achieve the equilibration of the
nasal mucosa.
The total duration of the bioconversion/permeability studieswas op-
timized from 150min to 120min because this timeframe allowed us to
obtain the desired results and is already extensive enough. Additionally,
there is previous indication that after being in diffusion chambers for
2 h, the epithelium of porcine nasalmucosa does not suffer considerable
morphological changes, as observed by histological analysis, while
swelling/edema and epithelial cell loss occurred after longer incuba-
tions (Wadell et al., 1999).
3.2. Analytical Method Development and Optimization
3.2.1. Development and Optimization of the Chromatographic Conditions
Since the desired application of this analytical method was to simul-
taneously determine the concentrations of FOS, PHT, and HPPH in sam-
ples from ex vivobioconversion and permeability studies, the aimwas to
use a common detection system (DAD) and the simplest chromato-
graphic elution conditions (isocratic), which require less complex and
expensive equipment. The mobile phase was optimized regarding the
organic solvent (acetonitrile ormethanol), aqueous component compo-
sition and pH and aqueous-organic components ratio. Concerning the
choice of organic solvent, acetonitrile was tested at 17.5–25% (v/v) but
was replaced by methanol (35–40%, v/v) due to its more favorable po-
larity that allowed changing the order of elution of HPPH and FOS,
delaying the latter, in order to avoid interferences at the beginning of
the chromatographic run. Higher percentages of both organic solvents
led to shorter run times but also to an overlap of the peaks of both the
analytes and IS with interferences. The aqueous component pH was
evaluated on the range of 3.0–6.5. Only FOSwas affected by this change,
with lower values of pH leading to higher retention times, which pro-
vided a better peak separation fromHPPH and avoidance ofmajor inter-
ferences. The inclusion of triethylamine in the aqueous component was
also tested because it is described to reduce peak tailing and asymmetry
(Reta and Carr, 1999), which was also verified here, with the effect
being more pronounced in the case of FOS. As a result of this optimiza-
tion process, the selected mobile phase was composed by an aqueous
componentwith 10mMNaH2PO4 and 0.25% triethylamine (v/v), pH ad-
justed to 3.0 with HCl, and methanol as the organic component, mixed
in a ratio of 64:36, v/v, respectively. Using this mobile phase, the elution
order of the compounds was HPPH, FOS, PHT and IS (Fig. 2).
The influence of column temperatures of 30 and 35 °C was ap-
praised, with the former being preferred because, even though the
higher temperature resulted in shorter retention times and narrower
peaks for all analytes, it had a negative impact in peak resolution.
Eleven compounds were analyzed in order to select a suitable IS to
correct for experimental variability during sample preparation and
analysis in the course of the first optimization trials (chlorpropamide,
coumarin, 10,11-dihydrocarbamazepine, gatifloxacin, ketoprofen, oxaz-
epam, paroxetine, tamoxifen, tolbutamide, venlafaxine and warfarin).
10,11-Dihydrocarbamazepine was ultimately chosen due to the
Fig. 2. Representative chromatograms obtained by the developed LCmethod at 215 nm. A - Blankmatrix. B - Matrix spikedwith the analytes at the concentration of the LLOQ (0.2 μg/mL)
and internal standard. HPPH: 5-(4-hydroxyphenyl)-5-phenylhydantoin; FOS: Fosphenytoin; PHT: Phenytoin; IS: Internal standard.
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peaks and assessment of the performance of the chromatographic sep-
aration until the end of each run and because it displayed an adequate
chromatographic behavior and high absolute recovery.
Several wavelengths ranging from 210 to 280 nm were assessed
using the DAD (based on values already described in the literature for
these analytes in different matrices (Alvariza et al., 2013; Burstein
et al., 1999; Cwik et al., 1997; Ferreira et al., 2014; Kapoor and Siegel,
2013; Kugler et al., 1998; Serralheiro et al., 2013a)) in order to choose
the ones that offered the best equilibrium between selectivity and sen-
sitivity. A wavelength of 215 nm was selected for the detection of both
the three analytes and IS because it granted a stable baselinewith amin-
imal level of interferences at the relevant retention times, allowing the
achievement of good LLOQs.
3.2.2. Optimization of the Sample Preparation Procedure
Considering the vast amount of samples that were/are supposed to
be analyzed with this analytical method, the objective was to develop
a fast, simple and inexpensive sample preparation procedure that con-
ferred high absolute recoveries for both the analytes and IS, to increase
the sensitivity of the assay to the furthest extent possible, andwas high-
ly reproducible. Since the matrix obtained from the bioconversion and
permeability studies was fairly simple and only contained residual
amounts of proteins, it became clear that a simple protein precipitationstep followed by centrifugation would be sufficiently efficient for the
extraction of the analytes. The tested precipitating agents were metha-
nol, trichloroacetic acid 20% and PCA 7 and 10%. Methanol was able to
adequately precipitate the proteins and provided a stable baseline
with only some interferences during the first minute of the chromato-
graphic run but was excluded due to the volume that was necessary
to add to the samples to effectively precipitate the proteins, with the
consequent dilution of the samples (1:2). Trichloroacetic acid was im-
mediately excluded because it had a high absorbance at the tested
wavelengths, resulting in a wide peak that eluted for the first 3 min of
the chromatographic run and interfered with the retention times of
some of the analytes. PCA 10% was ultimately selected because its use
resulted in an appropriate protein precipitation, a stable baseline, with
the major interferences eluting during the first 2 min of the chromato-
graphic run, and required a minimal dilution of the samples, which in
turn allowed obtaining the most sensitivity.
Other aspect that required careful consideration was the need to
fully stop the conversion of FOS to PHT during sample manipulation
and storage in the caseswhere the prodrugwas present in the donor so-
lution. Since immediately putting and handling the samples on ice only
provided a partial and, therefore, insufficient solution, the collection of
the samples to microtubes containing 20 μL of PCA 10% followed by ag-
itation by vortex was tested, with the results showing that this proce-
dure caused a total inactivation of the enzymatic degradation/
Table 2
Mean inter- and intra-day precision (% of the coefficient of variation, CV) and accuracy
(%bias) for the determination of 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH),
fosphenytoin (FOS) andphenytoin (PHT) in quality control (QC) samples at the lower lim-
it of quantification (QCLLOQ), low (QC1), medium (QC2) and high (QC3) concentrations of















HPPH QCLLOQ 0.2 3.4 7.9 2.3 9.8
QC1 0.6 2.4 2.2 1.0 2.7
QC2 15 2.7 5.6 1.9 3.7
QC3 27 1.5 4.3 3.0 1.0
QCDil 150–N15 5.2 1.1 1.7 3.2
FOS QCLLOQ 0.2 10.0 16.5 8.6 13.1
QC1 0.6 4.9 2.2 1.2 2.6
QC2 15 2.3 2.6 1.9 0.8
QC3 27 1.6 4.2 3.2 1.0
QCDil 150–N15 5.3 −1.9 1.8 −0.1
PHT QCLLOQ 0.2 5.6 4.8 1.6 6.8
QC1 0.6 3.2 1.2 1.4 2.6
QC2 15 2.6 0.7 2.0 −1.1
QC3 27 1.5 3.7 3.5 0.0
QCDil 150–N15 5.5 −1.4 1.8 0.8
Table 3
Absolute recovery and precision (% of the coefficient of variation, CV) of 5-(4-
hydroxyphenyl)-5-phenylhydantoin (HPPH), fosphenytoin (FOS), phenytoin (PHT) and
internal standard (IS) from quality control (QC) samples at low (QC1), medium (QC2)
and high (QC3) concentrations of the calibration curve range (n = 5 for the analytes and
n = 15 for the IS).
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procedure constituted a strategy that simultaneously precipitated all
the proteins and terminated the bioconversion of FOS, thus eliminating
any inaccuracy of the results due to the continued formation of PHT
after sampling. Samples were frozen at this point and simply thawed
at room temperature before adding the IS and centrifuging them to ob-
tain the supernatants that were injected into the chromatograph, fur-
ther expediting the sample preparation.
3.3. Analytical Method Validation
3.3.1. Selectivity
After analyzing the extracts of blank matrix samples from six differ-
ent sources and comparing them with matrix samples spiked with the
analytes at the LLOQ and IS, no significant interferences from endoge-
nous compounds, metabolites or degradation products were found at
the retention times of HPPH, FOS, PHT and IS (approximately 2.7, 3.7,
8.4 and 12.6 min, respectively), proving the selectivity of the method
(Fig. 2).
3.3.2. Linearity
Linearity was evaluated with calibration standards spanning from
0.2 to 30 μg/mL. As there was lack of random distribution of the error
in the residuals vs concentration plot (heteroscedasticity after applying
an F-test), a weighted linear regression analysis was performed as pre-
viously described (Almeida et al., 2002). The 1/y2 weighting factor was
selected for all analytes because it offered the best goodness of fit, con-
sidering the plots of percentage relative error (%RE) vs concentration
and the sum of absolute %RE values across the concentration range.
The back-calculated concentrations of the calibration standards for all
analytes were within the deviation from the nominal concentrations
recommended by the FDA and EMA guidelines, ranging from −11.2 to
16.2% for the LLOQ and from −6.8 to 9.6% for the other calibration
standards.
The obtained calibration curves were therefore linear for the three
analytes over the complete concentration range (Table 1). Since the
total plasmatic therapeutic window of PHT is 10–20 μg/mL (Stella,
1996), most of the chromatographic conditions described in
Section 2.6.2 might be useful in future in vivo pharmacokinetic studies
of the chosen formulations, after a suitable sample preparation and an-
alyte extraction procedure has been developed and optimized for the
relevant matrices (brain and plasma).
3.3.3. LLOQ, Precision, Accuracy and Dilution Integrity
The LLOQs for HPPH, FOS and PHT were experimentally defined as
0.2 μg/mL with both an adequate inter- and intra-day precision
(CV ≤ 10.0%) and accuracy (bias between 4.8 and 16.5%) (Table 2). The
achieved LLOQ for FOS is especially good since it is lower than the
ones reported in the literature (Cwik et al., 1997; Kapoor and Siegel,
2013).
Regarding the QC samples covering the low, medium and high con-
centration spectrum of the calibration curve range, the inter and intra-
day precision (CV ≤ 4.9%) and accuracy (bias ranging from −1.1 to
5.6%) (Table 2) were within the values recommended by the FDA andTable 1
Mean calibration curve parameters for 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH),
fosphenytoin (FOS) and phenytoin (PHT) obtained with the weighted linear regression
analysis using the 1/y2 weighting factor (n = 5).
Analyte Concentration range (μg/mL) Equationa r2
HPPH 0.2–30 y = 0.000036 × −0.000993 0.9989
FOS 0.2–30 y = 0.000023 × −0.000614 0.9996
PHT 0.2–30 y = 0.000035 × −0.000392 0.9996
a y represents analyte-IS peak area ratio; x represents analyte concentration (μg/mL).EMA guidelines, showing that the described LC analytical method is re-
producible and accurate over the established concentration range.
Concerning the dilution integrity evaluation after a tenfold dilution
of theQCDil sampleswith blankmatrix, the inter and intra-day precision
(CV ≤ 5.5%) and accuracy (bias between−1.9 and 3.2%) (Table 2) were
also acceptable according to the criteria established by the FDA andEMA
guidelines, which is especially important in this case since a dilution of
the samples collected from the donor chambers was often required.
3.3.4. Recovery
The absolute recoveries for all analytes at the three studied concen-
tration levels (low, medium and high) were extremely high, ranging
from 98.5± 4.4% to 100.1± 5.6% and exhibited a high level of precision
(CV ≤ 5.6%) (Table 3). These values show that the developed sample
preparation procedure led to a complete recovery of the analytes from
thematrix obtained from theUssing chambers, and allowed the present
analytical method to reach a high degree of sensitivity since no analyte
was lost during sample preparation. Furthermore, an absolutemean re-
covery of 101.7 ± 3.4% with a precision of 3.4% was achieved for the IS
(Table 3). In combination, these results demonstrate that the extent of






HPPH 0.6 98.8 ± 5.5 5.5
15 98.7 ± 1.8 1.8
27 98.5 ± 4.4 4.5
FOS 0.6 99.2 ± 5.5 5.5
15 98.7 ± 1.8 1.8
27 98.7 ± 4.6 4.7
PHT 0.6 100.1 ± 5.6 5.6
15 99.3 ± 1.9 1.9
27 98.6 ± 4.8 4.9
IS 14.3 101.7 ± 3.4 3.4
68 D. Antunes Viegas et al. / European Journal of Pharmaceutical Sciences 89 (2016) 61–723.3.5. Stability
All the analytes were stable at the two studied concentrations levels
(low and high), in conditions likely to be encountered in every step of
the analytical method, namely, during sample handling, storage and
analysis. The stability/reference samples ratio ranged from 94.6 to
104.3% (Table 4), which are well within the values recommended by
the FDA and EMA guidelines. Specifically, the analytes were shown to
be stable in unprocessed samples at room temperature for 4 h and
stored at−20 °C for 28 days and in processed samples at room temper-
ature for 24 h. Importantly, the results obtainedwith QC3FOS, which only
contained FOS, were similar to the ones obtained with QC3, that com-
prised a mixture of the three analytes, demonstrating that the use of
PCA 10% in the sample preparation did not allow the continued conver-
sion of FOS to PHT by inhibiting the activity of the alkaline phosphatases
present in the matrix.
3.4. Bioconversion and Permeability Studies
3.4.1. Ex vivo Bioconversion
The existence of in situ bioconversion of phosphate prodrugs into the
active drug by the nasal mucosa would increase the interest of the
prodrug strategy, since it is expected to increase the total permeation
of the drug. In the ex vivo studies performedwith porcine nasal mucosa
mounted in Ussing chambers and simple prodrug buffered solutions,
the bioconversion of FOS to PHTwas detected at a rate ranging from ap-
proximately 0.26 to 3.14 μM/min/cm2. The bioconversion rate increased
with both time (two-way ANOVA, p-value b 0.0001), which suggests a
diffusion-limited process, and FOS donor solution concentration (two-
way ANOVA, p-value b 0.0001) (Fig. 3). These results demonstrate, for
the first time, the existence of alkaline phosphatase activity in this tis-
sue, resulting in the bioconversion of FOS to PHT. Importantly, if an
ex vivo nasal mucosa model comprising a high dilution of the enzymes
present in the mucus due to rinsing and the large chamber volumes
has this level of bioconversion activity, the in vivo potential is very
promising. In fact, by following the procedure described in Section 2.5,
it was possible to detect the bioconversion of FOS to PHT by nasal
mucus from healthy human volunteers at all sampling times (1, 2.5
and 4 h), which clearly indicates that even just themucus displays phos-
phatase activity (data not shown). This means that the strategy envis-
aged by Kapoor et al. (Kapoor and Siegel, 2013), based on adding
alkaline phosphatase to the formulation to facilitate drug absorption,
is unnecessary.
Regarding the possible in situmetabolism of PHT to HPPH, it was not
possible to detect the metabolite either in the donor or receiver cham-
bers in any of the bioconversion and permeability studies, independent-
ly of drug concentration. This lack of PHT metabolism by the nasal
mucosa, at least at detectable levels, can also impact the potentialTable 4
Stability of 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH), fosphenytoin (FOS) and
phenytoin (PHT) in unprocessed and processed quality control (QC) samples at low
(QC1) and high (QC3 and QC3FOS) concentrations of the calibration curve range under con-
















HPPH QC1 0.6 96.6% 96.8% 104.3%
QC3 27 97.1% 97.9% 98.2%
FOS QC1 0.6 96.7% 97.9% 100.3%
QC3 27 97.2% 99.1% 98.4%
QC3FOS 27 94.6% 99.0% 99.8%
PHT QC1 0.6 95.9% 97.6% 103.4%
QC3 27 96.9% 98.6% 98.4%success of the strategy of administering FOS by the intranasal route in
a verymeaningful way since the active drug is not lost due tometabolic
conversion during absorption, which can augment its bioavailability.
This can possibly be explained by the fact that even though the exis-
tence of CYPs in the nasal cavity has been reported in the literature,
the predominant isoforms are CYP1A, CYP2A and CYP2E, whereas PHT
is mainly metabolized by CYP2C9/10 (Chollet, 2002; Wu et al., 2008).
3.4.2. Transepithelial Electrical Resistance
After performing several preliminary studies to evaluate the TEER of
different regions of the cavity nasal mucosa originating from both nasal
cavities of the same pig or using distinct pigs, it soon became clear that
this parameter presents a high degree of variability, even between adja-
cent mucosal pieces. Mucosas presenting either very low, very high or
highly variable TEER during the preincubation stage were replaced,
and TEER was controlled in all used mucosas before adding the donor
solution and at the end of the 120 min incubation, and the average
TEER (between the beginning and the end of the incubation) was calcu-
lated. The average TEER from all the bioconversion/permeability studies
ranged from 21 to 30 Ω·cm2. Initial drug concentrations in the donor
chambers were quantified experimentally and are summarized in
Table S1 (Supplementary material). There were statistical significant
differences between the TEER of the study with FOS in KRB at
3398 μM and the TEER of the studies with FOS in KRB at 304 μM and
PHT in KRB at 313 μM (Fig. 4).
These TEER values were lower than the reference figures described
in the literature (Osth et al., 2002a;Wadell et al., 1999). However, no di-
rect comparisons can be established since a different nasal cavity region
was selected formucosa excision, and it has been reported that both the
TEER and other electrophysiological parameters can fluctuate severely
depending on the exact region of the nasal cavity fromwhere themuco-
sa was excised (Osth et al., 2002a).
Since TEER serves as a surrogate measure of the integrity of the tis-
sues (Fortuna et al., 2012), the TEER influence in drug permeability
was modeled by linear regression analysis in the following data sets,
which complied with the acceptance criteria described in Section 2.7:
PHT in KRB at 313 μM, FOS in KRB at 304 μM and FOS in KRB at
3398 μM. A novel data analysis method was developed (described in
Section 2.7) to weight the permeability results and compensate for the
interference of the TEER of each individual mucosa, which allowed us
to safely compare all data sets.
3.4.3. PHT and FOS Permeability and pH Influence
Drug permeability is usually expressed as the apparent permeability
coefficient (Papp) (Fortuna et al., 2012; Osth et al., 2002a; Pund et al.,
2013; Wadell et al., 1999). However, the linear regression analysis
model that we developed required the logarithmic transformation of
this coefficient to obtain a normal distribution, and we will express it
as ln(Papp). We started with the highest PHT concentration that we
were able to attain in KRB (313 μM) and used similar and increasing
FOS concentrations to make the necessary comparisons and study the
concentration effect. At comparable PHT and FOS concentrations, de-
spite the fact that the two-way ANOVA showed a statistical significant
difference between the ln(PappPHT) of both compounds (p-value =
0.0028), this disparity was really small, such that there were no statisti-
cal significant differences at any of the individual studied time points
using the Sidak post-hoc test (Fig. 5, A). Hence, it is safe to assume
that the use of the prodrug instead of the active drug did not constitute
a severe hindrance to the overall drug permeation across the nasal
mucosa.
This similar overall drug permeation across the nasal mucosa may
have been due to the combination of the bioconversion of FOS to PHT,
previously to drug permeation, and permeation of the prodrug itself,
followed by bioconversion. Despite the hydrophilic nature of FOS, this
last statement is supported by the fact that when the highest prodrug
concentration (7378 μM) was tested, FOS was quantifiable in the
Fig. 3. Surface plot of the mean ex vivo bioconversion rate of fosphenytoin (FOS) to phenytoin by porcine nasal mucosa in function of time and FOS concentration as calculated at 30 to
120 min of incubation in KRB at pH 7.4 (n = 8–10). KRB: Krebs-Ringer Bicarbonate buffer.
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evated concentrations, its permeation rate overcame the bioconversion
rate (Fig. 5, C).
By increasing the FOS concentration in the donor solution, ln(PappPHT)
tended to similar equilibrium values as the assay progressed, but higher
prodrug concentrations led to a faster attainment of that equilibrium
because the starting ln(PappPHT) was greater (Fig. 5, B). Indeed, taking
into account the studied FOS concentrations, there were only statistical
significant differences between the ln(PappPHT) values at 30 min (3398 vs
7378 μM, p-value b 0.001) and in one case at 60 min (304 vs 7378 μM,
p-value b 0.01), using a Sidak post-hoc test. This reinforces the possible
advantage of using the prodrug strategy since, due to its large intrinsic
solubility, FOS can be used at much higher concentrations than PHT,
presenting a good apparent permeability sooner, which is crucial
when using the intranasal route of administration due to the difficulties
in retaining drug formulations in the nose. In combination with the re-
sults from the bioconversion studies, the conclusions that can be drawn
from these data pave theway for the success of using prodrugs not onlyFig. 4. Average transepithelial electrical resistance (TEER) of the porcine nasal mucosas
obtained from the measurements made in each experiment at the end of the
preincubation time and drug/prodrug incubation for all phenytoin and fosphenytoin
bioconversion/permeability studies (n = 5–10). Mean ± SEM. FOS: Fosphenytoin; PHT:
Phenytoin. * represents a statistical significant difference between the average TEER of
the studies (p-value b 0.05) after performing an analysis of variance (one-way ANOVA),
followed by a Tukey post-hoc test.of PHT but any other CNS-active drug that is equally limited by low sol-
ubility and can benefit from the synthesis of phosphate prodrugs.
Taking into consideration the higher polarity and charged nature of
FOS in comparison to PHT, it is reasonable to assume that the former
mainly permeates the nasal mucosa using the paracellular pathway
through hydrophilic porous and tight junctions, while the latter should
predominantly resort to the transcellular route due its higher
lipophilicity.
In order to better compare our results to the ones available in the lit-
erature, an exponential transformation of the ln(PappPHT/FOS) results can be
performed, leading to PappPHT/FOS values ranging from approximately 3.8 to
8.7 × 10−6 cm/s, depending on the time and initial donor drug concen-
tration. These values are within the scope of the ones obtained in por-
cine nasal mucosa by Wadell et al. for the permeation markers D-
glucose and mannitol (6.6 and 5.7 × 10−6 cm/s, respectively) (Wadell
et al., 1999), which strongly suggests that the integrity of our tissues
was not compromised.
Since there is a correlation between permeability in the nasal cavity
and drug charge, lipophilicity and molecular weight, it is also useful to
compare the Papp of the studied active drug (PHT)with the ones report-
ed for molecules with similar physicochemical properties. In that re-
gard, an in situ gel of venlafaxine displayed a Papp of approximately
5.9 × 10−6 cm/s in an ex vivo study with sheep nasal mucosa (Pund
et al., 2013), while a saline and Krebs-Ringer solution (pH 7.4) of diaze-
pam presented a Papp of about 6.8 and 6.6 × 10−6 cm/s, respectively, in
rabbit nasal mucosa (Maitani et al., 1997). Once again, these values are
relatively similar and in accordancewithwhat we obtained for PHT and
FOS.
Since, to the best of our knowledge, there has not yet been per-
formed any ex vivo permeability study in nasal mucosa with PHT or
FOS, there is not direct term of comparison. However, there is an
ex vivo study with PHT in rat jejunum that presented a Papp of approxi-
mately 22 × 10−6 cm/s (Watanabe et al., 2004), which shows that PHT
permeates across intestinal mucosa to a much higher extent than nasal
mucosa.
The previous results were obtained at pH 7.4, but the physiological
pH of the nasal mucosa is 5.0–6.5 (Bahadur and Pathak, 2012). Further-
more, at lower pH, FOS is expected to be less charged considering its pKa
of 2.04 and 5.89 (Fischer et al., 2003). Therefore, we evaluated the influ-
ence of a pH change to 4.5 in PHT and FOS permeability. Surprisingly,
the decrease of pH from 7.4 to 4.5 led to a significant reduction of the
permeability of both the active drug (Fig. 6, A) and the prodrug (Fig. 6,
Fig. 5. Natural logarithm of the apparent permeability coefficients of phenytoin [ln(PappPHT)]
and fosphenytoin [ln(PappFOS)] at different drug/prodrug concentrations. A - Comparison
of ln(PappPHT) at identical PHT and FOS donor solution concentrations in KRB at pH 7.4
(n = 6–9). B - Comparison of ln(PappPHT) at different FOS donor solution concentrations in
KRB at pH 7.4 (n = 6–10). C - Ln(PappFOS) with FOS donor solution of 7378 μM in KRB at
pH 7.4 (n = 7). Mean ± SEM. Data points are missing at 30 min in graph A and B
because PHT concentrations in the receiver chambers were below the lower limit of
quantification of the analytical method. FOS: Fosphenytoin; KRB: Krebs-Ringer
Bicarbonate buffer; PHT: Phenytoin; (w): Weighted ln(PappPHT).
Fig. 6.Natural logarithm of the apparent permeability coefficients of phenytoin [ln(PappPHT)]
and fosphenytoin [ln(PappFOS)] at different pH. A - Comparison of ln(PappPHT) at similar FOS
donor solution concentrations in KRB at pH 7.4 and phosphate buffer at pH 4.5 (n = 5–
7). B - Comparison of ln(PappFOS) at similar FOS donor solution concentrations in KRB at
pH 7.4 and phosphate buffer at pH 4.5 (n = 5–7). Mean ± SEM. FOS: Fosphenytoin;
KRB: Krebs-Ringer Bicarbonate buffer; PHT: Phenytoin. *, ** and *** represent a
statistical significant difference between ln(PappPHT) or ln(PappFOS) at each time point in
function of pH (p-value b 0.05, b0.01 and b0.001, respectively), after performing an
analysis of variance (two-way ANOVA), followed by a Sidak post-hoc test.
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nificance of the global effect of pH as the source of variationwas charac-
terized by a p-value of 0.0001 when PHT was quantified in the receiver
chambers and of 0.0127 for the assay of FOS. These results contradict
what is reported in the literature for other drugs in ex vivo studies
made in rabbit nasal mucosa, where a reduction of pH increased the
permeability of diazepam, lucifer yellow (Maitani et al., 1997) or even
a protein, namely, insulin (Maitani et al., 1992).
Considering thatmost pH-related changes in permeability are due to
the alteration of drug ionization and/or charge, thesefindings are partic-
ularly surprising for FOS since at an acidic pH, it theoretically presents
mainly one negative charge instead of the two at physiological pH,
which should have led to a lower electrostatic repulsion from the nega-
tive charge of the nasal epithelium and higher permeation. However,
these results might hint that FOS permeation depends on other factors
such as active transport that were partly impaired by the lower pH, be-
sides simple diffusion based on a concentration gradient.Even though the natural pHof nasalmucosa is slightly acidic, the use
of a higher value such as 7.4, for whichwe obtained better permeability
results for both PHT and FOS and showed greater potential, should not
be problematic. For example, the nasal mucosal irritation caused by
pH changes was evaluated in rats using in situ nasal perfusion and it
was found that phosphate buffers with pH 3–10 led to a minimal and
equivalent release of total protein and, specifically, of lactate dehydro-
genase and 5′-nucleotidase at pH 8, which revealed a good intracellular
andmembrane integrity, respectively (Pujara et al., 1995). Furthermore,
the use of physiological pH can also prove to be advantageous from a
safety point of view based on the findings of a study that performed
an in vitro evaluation of the rat tracheal ciliary beat frequency, which
is a good indicator of mucotoxicity. Notably, van de Donk et al. reported
that this parameter was not influenced by Locke-Ringer solutions with
pH ranging from7 to 10, while lower or higher values decreased the fre-
quency (van de Donk et al., 1980).
4. Conclusions
The developed ex vivo bioconversion/permeability evaluationmeth-
od combined with the novel TEER-effect modeling procedure in data
analysis is fast, inexpensive, and accurate and it constitutes a valuable
tool for the future comparative evaluation of different formulations,
while respecting the 3Rs principles by reducing the number of animals
used in experimentation. Importantly, it already allowed us to demon-
strate the existence of phosphatase activity and FOS bioconversion in
nasal mucosa, as well as the favorable nasal permeability of this
71D. Antunes Viegas et al. / European Journal of Pharmaceutical Sciences 89 (2016) 61–72phosphate ester prodrug. Overall, this study demonstrates the feasibility
of formulating phosphate prodrugs of poorly soluble CNS-active drugs
in order to increase the solubilized drug doses administered through
the nasal route, thus improving direct nose-to-brain drug delivery.Acknowledgements
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